Cachexia could be the next blockbuster area in cancer therapeutics because of its link to survival outcomes. Physician and researcher Dr. Daniel L Marks discusses the historial challenges to ...

With cachexia, the muscles in your body will waste away regardless of how much you eat. The condition causes severe weight loss. (Photo Credit: Dr P. Marazzi/Science Source) Cachexia (aka “wasting ...

ART27.13 shows promise in reversing weight loss and increasing lean body mass in cancer anorexia-cachexia syndrome patients, with a significant difference compared to placebo. The drug's mechanism ...

New York, USA, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cancer Cachexia Clinical Trial Pipeline Shows Potential with Active Contributions from 18+ Key Companies | DelveInsight The cancer cachexia ...

Cachexia in older SCLC patients leads to inferior survival rates and increased treatment complications, such as dose reductions and incomplete chemotherapy courses. Patients with cachexia had ...

We would like to thank Drs Molfino and Imbimbo 1 for their thoughtful response to our Call to Improve Coding of Cancer-Associated Cachexia. Their letter reinforces key challenges in the diagnosis, ...

CatalYm has announced promising new data on its lead drug candidate, visugromab, at the 17th International Conference on Sarcopenia, Cachexia & Wasting Disorders (SCWD). The data from the ongoing ...

Maintaining good health and well-being is crucial for how well patients respond to cancer treatments. Unfortunately, cachexia, or involuntary weight loss, is a major concern for many individuals with ...

The prevalence of cancer cachexia varies among different cancer types, with pancreatic, hepatobiliary, and oesophagogastric cancer having notably high rates Assess the patient for cancer cachexia in ...

Cachexia is a common complication of cancer and is associated with an increased risk of death. The level of growth differentiation factor 15 (GDF-15), a circulating cytokine, is elevated in cancer ...

Sept. 14 (UPI) --A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical tests, drugmaker Pfizer announced Saturday. The experimental ...